Over the last few years, several preclinical studies have also been conducted in which various monoclonal antibodies against CD44 and CD44v6 were investigated in pancreatic cancer, acute myeloid leukaemia, breast cancer and chronic lymphocytic leukaemia [46–48]. This evidence concerns the gene CD44 and breast cancer.